Search - tctmd.com

Displaying 1 - 20 of 40

Sort: Relevancy | Date

News Features

Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too

Michael O'Riordan

December 18, 2019

News Daily News

Long-term Watchman Data Reassure: CAP and CAP2 Registries

Michael O'Riordan

December 02, 2019

Pulmonary Hypertension, Common in TAVR Patients, Linked to Lower Survival

Michael O'Riordan

November 26, 2019

News Conference News PCR London Valves 2019

Durable 1-Year Results with TriClip Edge-to-Edge Repair for TR: TRILUMINATE

Michael O'Riordan

November 25, 2019

News Conference News PCR London Valves 2019

TAVR in Bicuspid Aortic Valves: Insights From BIVOLUT-X

Michael O'Riordan

November 22, 2019

News Conference News PCR London Valves 2019

Solid 2-Year Outcomes for Portico, With Paravalvular Leak Rare

Michael O'Riordan

November 20, 2019

News Conference News PCR London Valves 2019

Signal of Impaired Sapien XT Durability in Midterm Follow-up

Michael O'Riordan

November 20, 2019

News Conference News PCR London Valves 2019

Two Small Series Support Role for Cerebral Protection in TAVR

Michael O'Riordan

November 18, 2019

News Conference News PCR London Valves 2019

Real-world Data Show MitraClip Benefit in COAPT-Ineligible Patients

Michael O'Riordan

November 17, 2019

News Daily News

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Michael O'Riordan

November 06, 2019

News Conference News TCT 2019

Predicting Final Valve Position After TAVR: Different Devices, Different Success

Michael O'Riordan

October 07, 2019

News Conference News TCT 2019

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

Michael O'Riordan

September 29, 2019

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

News Conference News TCT 2019

Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis

Michael O'Riordan

September 27, 2019

News Conference News TCT 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

Michael O'Riordan

September 27, 2019

News Conference News TCT 2019

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

Michael O'Riordan

September 25, 2019

News Daily News

MIDAS Touch: Anatomic Strategy Dramatically Lowers Pacemaker Rate With Evolut Valves

Michael O'Riordan

August 29, 2019

News Daily News

FDA: Class I Recall for Burst Balloons With Sapien 3 Ultra Delivery System

Michael O'Riordan

August 22, 2019

News Daily News

No Volume-Outcome Link With Watchman for LAA Closure? Single-Center Study

Michael O'Riordan

August 19, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

Advertisement

Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too

Long-term Watchman Data Reassure: CAP and CAP2 Registries

Pulmonary Hypertension, Common in TAVR Patients, Linked to Lower Survival

Durable 1-Year Results with TriClip Edge-to-Edge Repair for TR: TRILUMINATE

TAVR in Bicuspid Aortic Valves: Insights From BIVOLUT-X

Solid 2-Year Outcomes for Portico, With Paravalvular Leak Rare

Signal of Impaired Sapien XT Durability in Midterm Follow-up

Two Small Series Support Role for Cerebral Protection in TAVR

Real-world Data Show MitraClip Benefit in COAPT-Ineligible Patients

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Predicting Final Valve Position After TAVR: Different Devices, Different Success

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

MIDAS Touch: Anatomic Strategy Dramatically Lowers Pacemaker Rate With Evolut Valves

FDA: Class I Recall for Burst Balloons With Sapien 3 Ultra Delivery System

No Volume-Outcome Link With Watchman for LAA Closure? Single-Center Study

FDA Expands TAVR Indication to Low-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content